Small molecule FLT3 tyrosine kinase inhibitors

Research output: Contribution to journalArticle

Abstract

Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

Original languageEnglish (US)
Pages (from-to)1183-1193
Number of pages11
JournalCurrent Pharmaceutical Design
Volume10
Issue number11
DOIs
StatePublished - 2004

Fingerprint

Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Contrast Media
Mutation
3-tyrosine

Keywords

  • AML
  • FLT3
  • Kinase inhibitor
  • Tyrosine kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Small molecule FLT3 tyrosine kinase inhibitors. / Levis, Mark J; Small, Donald.

In: Current Pharmaceutical Design, Vol. 10, No. 11, 2004, p. 1183-1193.

Research output: Contribution to journalArticle

@article{02a2583a956a48939dc69b73b82ef9b8,
title = "Small molecule FLT3 tyrosine kinase inhibitors",
abstract = "Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.",
keywords = "AML, FLT3, Kinase inhibitor, Tyrosine kinase",
author = "Levis, {Mark J} and Donald Small",
year = "2004",
doi = "10.2174/1381612043452604",
language = "English (US)",
volume = "10",
pages = "1183--1193",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Small molecule FLT3 tyrosine kinase inhibitors

AU - Levis, Mark J

AU - Small, Donald

PY - 2004

Y1 - 2004

N2 - Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

AB - Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

KW - AML

KW - FLT3

KW - Kinase inhibitor

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=1842430924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842430924&partnerID=8YFLogxK

U2 - 10.2174/1381612043452604

DO - 10.2174/1381612043452604

M3 - Article

C2 - 15078134

AN - SCOPUS:1842430924

VL - 10

SP - 1183

EP - 1193

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 11

ER -